echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Novartis' latest clinical results of SMA gene therapy announced to improve multiple indicators in children

    Novartis' latest clinical results of SMA gene therapy announced to improve multiple indicators in children

    • Last Update: 2022-04-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On March 14, 2022, Novartis announced updated data from a clinical trial of Zolgensma (onasemnogene abeparvovec)


    Spinal muscular atrophy (SMA) is a rare, inherited neuromuscular disease and a leading genetic cause of infant mortality


    Zolgensma loaded a transgene that normally expresses the SMN protein into an AAV9 viral vector and modified the transgene to increase its ability to generate the SMN protein


    This open-label, single-arm, multicenter Phase 3 clinical trial was designed to evaluate the safety and efficacy of a single intravenous infusion of Zolgensma prior to onset of symptoms in patients with SMA with 2 or 3 copies of SMN2, in patients aged ≤6 week


    Final results for the cohort of patients with 3 copies (n=15):

    100% of patients (15/15) achieved the primary endpoint of unassisted standing for ≥3 seconds by 24 months of age, and 14 of them reached this milestone within the World Health Organization (WHO) normal developmental window


    Fourteen patients (93%) achieved independent walking, 11 of whom achieved this milestone within the WHO normal developmental window


    All patients (100%) were independent of nutritional and respiratory support during the trial


    All patients experienced at least one adverse event (AE) after dosing, of which 8 (53%) were considered treatment-related


    In addition, a post hoc analysis descriptively evaluated pooled data from one phase 1 and two phase 3 clinical trials to assess medullary function in children with symptomatic type 1 SMA following Zolgensma treatment, including those aged <6 months at the time of Zolgensma treatment.


    References:

    [1] Novartis data again demonstrate age-appropriate development when Zolgensma is used presymptomatically, and post-hoc data reveal SMA Type 1 patients could speak, swallow and maintain airway protection.


    (Original abridged)

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.